Medicure (TSE:MPH) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medicure Inc. has signed an agreement to acquire intellectual property from CanAm Bioresearch Inc., focusing on new chemical entities with potential therapeutic applications. The deal includes an initial cash payment and additional milestone payments upon filing and approval of new drug applications. Medicure expects these acquisitions to enhance its pharmaceutical development and commercialization efforts in the United States.
For further insights into TSE:MPH stock, check out TipRanks’ Stock Analysis page.